Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clostridium difficile: new therapeutic options.

Ashwin Balagopal1, Cynthia L Sears

  • 1Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 439, Baltimore, MD 21287, USA. abalago1@jhmi.edu

Current Opinion in Pharmacology
|July 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining genotoxic gut bacterial strains increases tumor burden and accelerates onset in a germ-free mouse model of colon carcinogenesis.

Cell reports·2026
Same author

Enterotoxigenic Bacteroides fragilis induces host genotype-specific colonic epithelial and immune responses in mice.

The Journal of infectious diseases·2026
Same author

An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gut.

Cell·2026
Same author

Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases.

Open forum infectious diseases·2026
Same author

Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases.

The Journal of infectious diseases·2026

Clostridium difficile disease, a significant cause of hospital-associated diarrhea, is prompting research into new treatments. Current management includes vancomycin or metronidazole alongside infection control measures.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Clostridium difficile disease is a primary cause of nosocomial diarrhea.
  • Emerging community-associated cases and increased virulence strains (BI/NAP1) are noted.
  • Rising metronidazole treatment failures and recurrent disease burden necessitate novel therapies.

Purpose of the Study:

  • To review emerging therapies for Clostridium difficile disease.
  • To highlight key agents under evaluation.
  • To reiterate current management strategies.

Main Methods:

  • Literature review of current and emerging Clostridium difficile treatments.
  • Analysis of clinical relevance for new therapeutic agents.
  • Synthesis of established management protocols.

Related Experiment Videos

Main Results:

  • Nitazoxanide, tolevamer, ramoplanin, and rifaximin are identified as key agents in development.
  • Vancomycin and metronidazole remain primary treatments.
  • Antibiotic discontinuation and infection control are crucial.

Conclusions:

  • New therapeutic agents are under investigation for Clostridium difficile disease.
  • Current management relies on established antibiotics and supportive care.
  • Addressing treatment failures and recurrence is a key focus for future therapies.